10 results on '"G. Scagliotti"'
Search Results
2. YI01.02 Why to Become a Member of the IASLC
- Author
-
G. Scagliotti
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,business.industry ,Library science ,Medicine ,business - Published
- 2019
- Full Text
- View/download PDF
Catalog
3. Rubella and measles seroprevalence among women of childbearing age, Argentina, 2002
- Author
-
Joseph P. Icenogle, A. Urquiza, Susana Prieto, William J. Bellini, D. Bi, D. Galimberti, M. S. Panero, M. Del Carmen Perego, Gustavo H. Dayan, C. Wolff, Susan E. Reef, G. Carroli, María Molina, and G. Scagliotti more...
- Subjects
Adult ,medicine.medical_specialty ,Adolescent ,Epidemiology ,Argentina ,Rural Health ,Antibodies, Viral ,medicine.disease_cause ,Measles ,Rubella ,Measles virus ,Pregnancy ,Risk Factors ,Seroepidemiologic Studies ,medicine ,Humans ,Seroprevalence ,Pregnancy Complications, Infectious ,Congenital rubella syndrome ,biology ,business.industry ,Age Factors ,Rubella virus ,Middle Aged ,biology.organism_classification ,medicine.disease ,Cross-Sectional Studies ,Infectious Diseases ,Immunization ,Immunoglobulin G ,Immunology ,Female ,business ,Research Article ,Demography - Abstract
To assess rubella and measles susceptibility among women of childbearing age we conducted a cross-sectional seroprevalence study in four cities and one rural area in Argentina. A convenience sample of women aged 15–49 years seeking care in public health-care institutions was selected (n=2804). Serum specimens were tested for rubella and measles IgG antibody titres. The overall susceptibility to rubella and measles was 8·8 and 12·5% respectively. Seroprevalence differences were found for both rubella (PP=0·002) across sites. Rubella seroprevalence was higher in women aged [ges ]40 years than in younger women (P=0·04). Measles seroprevalence tended to increase with age (PPP more...
- Published
- 2005
- Full Text
- View/download PDF
4. Delayed emesis induced by moderately emetogenic chemotherapy: Do we need to treat all patients?
- Author
-
O. Daniele, Andrea Lissoni, A. Antonuzzo, A. Maestri, P. Anastasi, Arcispedale S. Anna Ferrara, C. Basurto, Stefano Cascinu, S. Ramponi, M. Tagliaventi, V. Silingardi, E. Mantellim, G. Scagliotti, Fausto Roila, S. Ricci, D. Donati, F. Meriggi, M. Tonato, R. Tonachella, F. Di Costanzo, A. Santoro, M. Federico, E. Riva, P. Malacarne, Francesco Cognetti, A. Fabi, S. Tateo, M. Picciafuoco, A. D'Antona, G. Ferretti, A. Del Favero, F. Salvati, C. Boni, F. Nunziati, V. Ferraresi, M. A. Palladino, A. M. Mosconi, R. Sabbatini, Silvana Chiara, P. Zucchinelli, Elisabetta Campora, A. Antilli, A. Zaniboni, Pierfranco Conte, P. Barbian, G. Moretti, M. C. Locatelli, Enrico Cortesi, Giacomo Allegrini, V. De Angelis, G. Catalano, A. Trassoldati, S. Cirulli, Enzo Ballatori, and G. Ciccarese more...
- Subjects
Chemotherapy ,education.field_of_study ,Antiemetic Agent ,Nausea ,business.industry ,medicine.drug_class ,medicine.medical_treatment ,Population ,Hematology ,Granisetron ,Chemotherapy regimen ,Oncology ,Anesthesia ,medicine ,Vomiting ,Antiemetic ,medicine.symptom ,education ,business ,medicine.drug - Abstract
Summary Background The pattern and prognostic factors of delayed nausea and vomiting induced by moderately emetogenic chemotherapy have not yet been adequately studied. Patients and methods Data are derived from a large and well defined population of patients studied to evaluate the efficacy and tolerability of granisetron, dexamethasone and their combination in the control of acute emesis over repeated cycles of moderately emetogenic chemotherapy. Patients were monitored on days 2–5 without receiving any prophylactic treatment for delayed emesis. Results There were 395 evaluable patients at the first, 352 at the second and 319 at the third cycle of chemotherapy. Overall, 32.7% patients suffered symptoms of delayed vomiting and/or moderate-severe nausea at the first, 32.1% at the second and 35.1% at the third cycle of chemotherapy. More precisely, the incidence of delayed vomiting was 21.3% at the first, 18.5% at the second and 21.0% at the third cycle of chemotherapy, while the incidence of delayed moderate-severe nausea was 25.1%, 25.0% and 26.0%, respectively. The incidence of delayed vomiting and moderate-severe nausea was very low in patients who obtained good control of acute vomiting and moderate-severe nausea, but it remained substantial in patients who experienced them during the first 24 hours after chemotherapy. In fact, at first/second/third cycle of chemotherapy delayed vomiting occurred in 12.3%/11.8%/ 13.1% of patients who did not suffer from acute vomiting and in 54.1%/48.4%/55.9% of those who had acute vomiting, respectively. Similar data were obtained for delayed moderate-severe nausea. Conclusions Patients without acute vomiting or moderate-severe acute nausea may not need any antiemetic prophylaxis for delayed vomiting or nausea, while those with a history of acute vomiting or moderate-severe acute nausea should always be treated for delayed emesis. Selection bias and dependence effect of delayed emesis on acute emesis can cause misinterpretation of data derived from clinical trials in patients submitted to multiple cycles of chemotherapy. more...
- Published
- 1997
- Full Text
- View/download PDF
5. Combination Chemotherapy and Interferon α2b in the Treatment of Advanced Non-Small-Cell Lung Cancer
- Author
-
C. Fortini, M. Crippa, G. Genovese, Editta Baldini, A. R. Cruciani, Andrea Ardizzoni, Antilli A, F. Salvati, G. Scagliotti, M. Rinaldi, E. Soresi, E. Gatti, C Pennucci, R. Tonachella, R. Rosso, and G. B. Ferrara more...
- Subjects
Cisplatin ,Cancer Research ,medicine.medical_specialty ,Chemotherapy ,Cyclophosphamide ,business.industry ,medicine.medical_treatment ,Alpha interferon ,Combination chemotherapy ,medicine.disease ,Gastroenterology ,Surgery ,Oncology ,Internal medicine ,medicine ,Lung cancer ,business ,Survival rate ,Interferon alfa ,medicine.drug - Abstract
Thirty-four patients with previously untreated advanced non-small-cell lung cancer were treated with a combination of polychemotherapy and recombinant interferon. Chemotherapy consisted of cyclophosphamide, 400 mg/m2, epidoxorubicin, 50 mg/m2, and cisplatin, 40 mg/m2 (CAP) i.v. on day 4; recombinant alpha 2b interferon (r alpha 2b IFN) was given i.m. daily at the dose of 3-5 MU from days 1 to 7. The treatment was repeated every 4 weeks. In the 32 eligible patients the overall response rate was 19.3% (95% C.L. 7.4-37.4%). Non-hematologic toxicity consisted formerly in flulike symptoms and fatigue complained of by 37.5% and 31.2% of patients, respectively, and vomiting reported in 68.7% of patients; grade III-IV myelotoxicity was observed in 12.5% of cases. In no case was the toxicity life threatening. The median overall actuarial survival and progression-free survival were 37 and 20 weeks, respectively. This study indicates that the combination of CAP chemotherapy and r alpha IFN is feasible and active in the treatment of advanced non-small-cell lung cancer. more...
- Published
- 1991
- Full Text
- View/download PDF
6. Are the results obtained in randomized clinical trials on antiemetics sufficiently reproducible in clinical practice?
- Author
-
Enzo Ballatori, S. Ricci, C. Dazzi, A. Scanu, S. Morana, R. Saltarelli, V. De Angelis, F. Montinari, M. G. Mascia, F. Salinaro, Anna Maria Angelone, M. Tonato, S. Lucchino, Fausto Roila, G. Grecchi, P. Alessandroni, G. Favalli, B. Rugerri, Francesco Cognetti, Andrea Antonuzzo, R. Gareri, G. Ciccarese, M. Clerico, M. T. Ionta, D. Donati, E. Recaldin, C. Basurto, B. Massidda, A. Contu, Maurizio Nicodemo, C. Zara, N. Olmeo, Pierfranco Conte, Antonella Mattei, F. Buzzi, G. Scagliotti, A. Nuzzo, G. Selvaggi, S. Tateo, A. Del Favero, M. C. Locatelli, A. Pazzola, Luca Galli, M. L. Bruno, S. Porrozzi, F Di Orio, M. A. Palladino, M. Picciafoco, V. Picece, Enrico Cortesi, and P. Masiero more...
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,5-HT3 antagonists ,Vomiting ,Alternative medicine ,Antineoplastic Agents ,law.invention ,Drug Utilization Review ,Randomized controlled trial ,law ,Neoplasms ,Medicine ,Humans ,Intensive care medicine ,Aged ,Randomized Controlled Trials as Topic ,Antiemetics ,Cisplatin ,Drug utilization review ,Oncology ,business.industry ,Research ,Reproducibility of Results ,Middle Aged ,Prognosis ,Clinical Practice ,Logistic Models ,Italy ,Anesthesia ,Female ,business ,Emetics - Abstract
To evaluate whether the incidence of emesis in patients undergoing cisplatin chemotherapy and receiving the standard antiemetic prophylaxis during daily clinical practice was similar to that obtained in antiemetic trials, a prospective study was carried out, adopting very wide eligibility criteria. In the first cycle of chemotherapy, 308 consecutive adult patients were evaluated, 112 in the second, and 89 in the third cycle. Results were compared with those obtained in three published randomized clinical trials. In the first cycle of chemotherapy, complete protection from acute vomiting/nausea was obtained by 78.9% (243/308) and 71.8% (221/308) of patients. These results were quite similar to those obtained in the three randomized studies: 79.7%/72.1%, 78.3%/71.4%, and 78.7%/77.2%. No significantly different results among these studies were obtained, even in the second and third cycles of chemotherapy. In conclusion, in patients undergoing cisplatin chemotherapy, the effectiveness of the same standard antiemetic prophylaxis is similar to the efficacy found in randomized clinical trials, regardless of the eligibility/exclusion criteria and the setting of the study. more...
- Published
- 2000
7. 15IN SYSTEMIC THERAPY. NON-SMALL CELL LUNG CANCER STAGE I AND II: TREATMENT STANDARDS AND NEW DEVELOPMENT
- Author
-
G. Scagliotti and S. Novello
- Subjects
Pulmonary and Respiratory Medicine ,Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Cancer ,medicine.disease ,Systemic therapy ,Internal medicine ,medicine ,Non small cell ,business ,Lung cancer - Published
- 2009
- Full Text
- View/download PDF
8. ROLE OF LAPAROSCOPIC ADRENALECTOMY FOR THE MANAGEMENT OF METASTASIS IN ADVANCED LUNG CANCER
- Author
-
R.M. Scarpa, G. Scagliotti, V. Volpe, M. Selvaggi, F. Ragni, Michele Billia, P. Novello, and F. Porpiglia
- Subjects
Oncology ,medicine.medical_specialty ,Laparoscopic adrenalectomy ,business.industry ,Urology ,Internal medicine ,General surgery ,medicine ,Cancer ,business ,Lung cancer ,medicine.disease ,Metastasis - Published
- 2008
- Full Text
- View/download PDF
9. 272 LAPAROSCOPIC ADRENALECTOMY FOR METASTASIS OF LUNG CANCER: REVIEW OF OUR EXPERIENCE
- Author
-
F. Porpiqlia, G. Scagliotti, R.M. Scarpa, G. Selvaggi, Massimiliano Poggio, Michele Billia, Julien Renard, Francesca Ragni, and A. Volpe
- Subjects
medicine.medical_specialty ,Laparoscopic adrenalectomy ,business.industry ,Urology ,General surgery ,medicine ,Cancer ,medicine.disease ,Lung cancer ,business ,Metastasis - Published
- 2007
- Full Text
- View/download PDF
10. 51 O The alpi trial: a randomized study of adjuvant chemotherapy for stage I-II-IIIA non-small cell lung cancer (NSCLC)
- Author
-
G. Scagliotti
- Subjects
Cancer Research ,Chemotherapy ,medicine.medical_specialty ,business.industry ,Mortality rate ,medicine.medical_treatment ,non-small cell lung cancer (NSCLC) ,medicine.disease ,law.invention ,Surgery ,Radiation therapy ,Oncology ,Randomized controlled trial ,law ,medicine ,Mucositis ,Adjuvant therapy ,Vindesine ,business ,medicine.drug - Abstract
In spite of over 20 studies published so far, the therapeutic role of adjuvant therapy in non-small cell lung cancer is still unsettled. Against this background, in January 1994 a large randomized trial (Alpi trial) was launched in Italy. The primary aims of this trial were to establish the survival gains from adjuvant MVP chemotherapy (Mitomyein C B mg/mq on day 1, Vindesine 3 mg/mq on days 1 and 8, Cisplatin 100 mg/mq on day 1 given every 3 weeks for 3 cycles) and to describe the impact of treatment toxicity on patients with NSCLC. Alpi protocol mandates that the referral of patients for postoperative radiotherapy be left to the discretion of the participant centre. Radiotherapy should be timetabled to begin after completing the chemotherapy. Radiotherapy should begin between the 22nd and 35th day since the end of chemotherapy cycles. For patients in the control arm, radiotherapy should begin between the 29th and 42nd day since surgery. Planned total dosage is 50–54 Gy in 5–6 weeks according to the chosen fractioning scheme. The study is planned to detect a 20% relative reduction in mortality for patients undergoing adjuvant MVP with 80% power at the 5% level of significance. Assuming a death rate of 50% at 5 years, it is established that 1500 patients would be necessary. As December 1995, a total of 499 patients have been enrolled into the study by 54 general hospitals across Italy. Patients’ characteristics were as follows: median age 62 years; males = 89%; Stage I = 38%, Stage II = 21%, Stage IIIA = 41%; Adenocarcinoma = 44%, Epidermoid = 48%, Large cell = 4%, Bronchioloalveolar = 4%. One hundrend forty five patients randomized to MVP were evaluable for toxicity assessment:: adjuvant chemotherapy was completed in 103 (71%), was interrupted for toxicity in 10 and refused in absence of severe toxicity by 11 patients; two patients discontinued treatment for death. Twenty-eight percent of patients experienced grade 3 toxicity, while grade 4 toxicity accounted lor 11% of patients. Radiotherapy was delivered in 210 patients: respectively in 9%, 55% and 67% of stages I, III & IIIa. Among the patients that underwent radiotherapy, mucositis was observed 45% of patients, (WHO III-IV in1.3%). At a median follow-up of 12 months 54 relapses and 36 deaths occurred. At one year Event Free and Overall Survival are 60% and 74% respectively. more...
- Published
- 1996
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.